Forecast

The analysts' average price target is €4.31 (+606.56%). The median is €4.31 (+606.56%).

Buy	2
Hold	1
Sell	0

News Go to news feed

Fractyl Health bets on one-time therapies to maintain weight after GLP‑1

Fractyl Health presented at the Canaccord growth conference its strategy to develop one-time metabolic treatments that address weight and root causes of diabetes. Lead program Revita showed sustained weight maintenance after GLP‑1 therapy in pilot studies and is now running a 300‑patient, approval‑relevant trial with initial 6‑month data due in early Q4; a regulatory submission based on those data is planned by year‑end. Rejuva, a gene‑therapy candidate for endogenous GLP‑1 production, received IND clearance and is approaching first-in-human use. Fractyl plans to commercialize through roughly 200–400 centers of excellence rather than a broad rollout; success depends on clinical and regulatory milestones. » More on de.investing.com
Fractyl Health beats EPS estimates, investors focus on REMAIN‑1 obesity data

Fractyl Health reported adjusted EPS of -$0.16, beating the estimate of -$0.25 (by 36%), driven by lower R&D spending and reduced cash burn. Operating cash consumption was about $16 million for the quarter; cash and cash equivalents of $47.1 million are expected by management to be sufficient into early 2027. No capital raises are planned ahead of the approval‑relevant Revita/REMAIN‑1 data. The market reaction was muted (stock at $0.68) as investors are primarily awaiting the upcoming REMAIN‑1 top‑line data in early Q4 2026 and a possible de‑novo filing at quarter end. » More on de.investing.com
Fractyl Health: Revita reduces yo‑yo effect after stopping GLP‑1 therapy

Fractyl Health reports from the REMAIN‑1 midpoint cohort that a single Revita‑DMR procedure reduced weight regain after one year by about 40% versus sham treatment. Participants with complete duodenal ablation >14 cm retained roughly 81% of their GLP‑1‑induced weight loss versus 48% in the control group; a subgroup with ≥17.5% initial loss retained about 84% versus 46%. The responder rate for weight maintenance was 73% overall and 91% for complete ablation; no serious procedure‑ or device‑related adverse events occurred. Fractyl expects first six‑month data from the pivotal cohort in early Q4 2026 and is targeting a possible De‑Novo submission to the FDA by the end of Q4 2026. » More on de.investing.com

Financials

In the last quarter, FRACTYL HEALTH INC. O.N. Aktie had revenue of €0 and net profit of -€22.38M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-22.38M	5.43%
EBITDA	-21.89M	6.60%

Fundamentals

Metric	Value
Market capitalization	€97.24M
Number of shares	158.65M
52-week high/low	€2.11 - €0.33
Dividends	No
Beta	2.32
P/E ratio	-0.65
PEG ratio	-0.01
P/B ratio	-67.73
P/S ratio	0.00

Company profile

Fractyl Health, Inc. ist ein Unternehmen für Stoffwechseltherapeutika und entwickelt Therapien zur Behandlung von Typ-2-Diabetes (T2D) und Adipositas. Das Unternehmen entwickelt das Revita DMR System (Revita), ein ambulantes Therapieverfahren zur dauerhaften Veränderung der Duodenaldysfunktion, einer pathologischen Folge einer fett- und zuckerreichen Ernährung, die beim Menschen T2D und Fettleibigkeit auslösen kann. Darüber hinaus entwickelt das Unternehmen Rejuva, eine neuartige Gentherapieplattform für die Bauchspeicheldrüse, die eine langfristige Remission von T2D und Fettleibigkeit ermöglichen soll, indem sie die Funktion von Stoffwechselhormonen in den Inselzellen der Bauchspeicheldrüse von Patienten dauerhaft verändert. Fractyl Health, Inc. war früher als Fractyl Laboratories Inc. bekannt und änderte am 09. Juni 2021 seinen Namen in Fractyl Health, Inc. Das Unternehmen wurde im Jahr 2010 gegründet und hat seinen Sitz in Lexington, Massachusetts.